Study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
Studies have shown that utilising a PARP inhibitor in the management of patients with metastatic…
Browsing: brca 2
First study of neoadjuvant use of PARP inhibitor shows promise for early-stage, BRCA breast cancer patients
In a small Phase II study of early-stage breast cancer patients with BRCA1/2 mutations, researchers…
Streamlined education gives women confidence and support on breast cancer genetic testing
Gabrielle Dunlevy, UNSW A streamlined model of education can be used to offer genetic testing…
Caution urged on speculative panel testing for hereditary breast cancer
Researchers at Peter MacCallum Cancer Centre are calling for greater caution in genetic testing for…
The enduring ‘Angelina effect’ on breast cancer awareness and gene testing
By Julia Medew – SMH. If there was ever any doubt about the magnitude of Angelina…
NICE approves tamoxifen as a preventative in UK – will Australian women be offered this treatment?
New guidance published by NICE a “game changer” for UK women with genetic risk of…